Avid-45 in frontotemporal dementia, Alzheimer's and normal controls

  • Research type

    Research Study

  • Full title

    A study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer’s disease and normal controls

  • IRAS ID

    4459

  • Sponsor organisation

    Avid Radiopharmaceuticals, Inc.

  • Eudract number

    2008-003597-18

  • ISRCTN Number

    N/A

  • Clinicaltrials.gov Identifier

    N/A

  • Research summary

    18F-AV-45 is a new agent that will allow doctors to look at changes in the brain of patients with Alzheimer's disease using a Positron Emission Tomography (PET) scanner. It is radioactively labelled by the short-living isotopflurine-18 (18F) and is injected intravenously in minute amounts prior to performing the imaging procedure. This PET tracer technique visualises a chemical, called amyloid-×ý peptide, that builds up in the brain of a patient with Alzheimer's disease. These deposits are called amyloid plaques and are a diagnostic hallmark of Alzheimer's disease in brain tissue. Until recently they could by detected only after patients' death at autopsy but not by diagnostic procedures during lifetime. 18F-AV-45 is expected to detect amyloid deposition in living patients with Alzheimer's disease and to distinguish them from patients with non-Alzheimer's disease related dementias. In this study, 10 healthy volunteers and 30 patients with either Alzheimer's disease or Fronto-temporal dementia (FTD), a dementia not associated with deposition of amyloid-×ý peptide, will be studied in order to look at the amount of accumulation of 18F-AV-45 in PET scans and to validate the utility of this tracer to distinguish between Alzheimer??s and non-Alzheimer??s disease.

  • REC name

    North East - Newcastle & North Tyneside 2 Research Ethics Committee

  • REC reference

    08/H0907/158

  • Date of REC Opinion

    1 Apr 2009

  • REC opinion

    Further Information Favourable Opinion